ART123 clinical trials
Also written ART-123 and thrombomodulin alfa.
How each study uses ART123 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2012 | 2 |
| 2016 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Asahi Kasei Pharma Corporation (3) · Asahi Kasei Pharma America Corporation (2) · Veloxis Pharmaceuticals (2) · Artisan Pharma, Inc. (1)
Studies
Open first, then newest update. How each study uses ART123 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer PatientsTerminatedPhase 1Veloxis PharmaceuticalsNCT05251727Written as thrombomodulin alfa
- Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon CancerCompletedPhase 2Asahi Kasei Pharma CorporationNCT02792842Written as ART-123 (3-day ART)
- A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based ChemoWithdrawnPhase 2Veloxis PharmaceuticalsNCT04492436Written as thrombomodulin alfa
- Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and CoagulopathyCompletedPhase 3Asahi Kasei Pharma America CorporationNCT01598831Written as ART-123
- The Safety And Efficacy of ART-123 in Subjects With Sepsis and CoagulopathyWithdrawnPhase 3Asahi Kasei Pharma America CorporationNCT03517501Written as ART-123
- Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisCompletedPhase 3Asahi Kasei Pharma CorporationNCT02739165Written as ART-123
- Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal ImpairmentCompletedPhase 4Asahi Kasei Pharma CorporationNCT01704001Written as ART-123
- Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular CoagulationCompletedPhase 2Artisan Pharma, Inc.NCT00487656Written as ART-123